{"schema_version":"1","generated_at":"2026-11-04T10:47:19.333Z","data_as_of":null,"url":"https://www.findmykol.com/kol/saravut-weroha","json_url":"https://www.findmykol.com/kol/saravut-weroha/profile.json","record_kind":"basic","profile_kind":"clinical","person":{"slug":"saravut-weroha","name":"Saravut Weroha","credential":"MD, PhD","specialty":"Medical Oncology","specialty_raw":"Medical Oncology","therapeutic_area":"Oncology","therapeutic_areas":["Oncology"],"institution":"Mayo Clinic","institution_url":"https://www.findmykol.com/institution/mayo-clinic","city":"Rochester","state":"MN","region":{"label":"Midwest","url":"https://www.findmykol.com/region/midwest"}},"identifiers":{"npi":"1043415144","orcid":"0000-0002-7130-7259","openalex":"A5104003158"},"summary":"Saravut Weroha is an Oncology physician affiliated with Mayo Clinic. OpenAlex indexes 56 publications with 726 citations (h-index 12).","overview":null,"focus":{"indications":[],"research_topics":["Oncology"]},"scholarship":{"works_count":56,"cited_by_count":726,"h_index":12,"latest_activity_year":2026,"source":"works"},"payments":{"company_count":4,"program_years":{"first":2021,"last":null},"rows_total":9,"shown":3,"withheld":6,"rows":[{"payer":"ABBVIE INC.","program_year":2025,"amount_usd":2356.25,"payment_count":1,"source_url":"https://openpaymentsdata.cms.gov/search?query=1043415144"},{"payer":"Eli Lilly and Company","program_year":2025,"amount_usd":1053,"payment_count":2,"source_url":"https://openpaymentsdata.cms.gov/search?query=1043415144"},{"payer":"ABBVIE INC.","program_year":2024,"amount_usd":108.63,"payment_count":1,"source_url":"https://openpaymentsdata.cms.gov/search?query=1043415144"}],"record_url":"https://openpaymentsdata.cms.gov/search?query=1043415144","source":"payments"},"prescribing":{"data_year":2024,"areas_total":5,"areas_shown":3,"areas":[{"area":"Cancer & immunology","share_pct":66.2,"classes_total":4,"classes":[{"class":"PD-1 inhibitor","setting":"administered","share_pct":34,"drugs":[{"name":"Pembrolizumab","share_pct":100}],"max_beneficiaries":17},{"class":"CD38-directed Cytolytic Antibody","setting":"administered","share_pct":30.6,"drugs":[{"name":"Daratumumab","share_pct":100}],"max_beneficiaries":14}]},{"area":"Metabolism & gastrointestinal","share_pct":30.7,"classes_total":2,"classes":[{"class":"Other antiemetics","setting":"administered","share_pct":25.5,"drugs":[{"name":"Fosaprepitant","share_pct":100}],"max_beneficiaries":17},{"class":"Serotonin-3 Receptor Antagonist","setting":"mixed","share_pct":5.3,"drugs":[{"name":"Palonosetron hcl","share_pct":52.1},{"name":"Ondansetron hydrochloride","share_pct":43.8},{"name":"Ondansetron Hcl","share_pct":4.1}],"max_beneficiaries":28}]},{"area":"Sensory organs","share_pct":2.5,"classes_total":1,"classes":[{"class":"Corticosteroid","setting":"mixed","share_pct":2.5,"drugs":[{"name":"Dexamethasone sodium phosphate","share_pct":85.2},{"name":"Dexamethasone","share_pct":14.8}],"max_beneficiaries":22}]}],"care_setting":{"dominant":"office","data_year":2024,"office_pct":100,"facility_pct":0},"source":"medicare"},"funding":{"award_count":5,"fiscal_years":{"first":2015,"last":2026},"rows_total":19,"shown":3,"withheld":16,"matched_by":"principal investigator name at an organization in the practice state","rows":[{"project":"P50CA136393","title":"Targeting a Metabolic Pathway to Treat Ovarian Cancer","fiscal_year":2026,"amount_usd":"284338","organization":"MAYO CLINIC ROCHESTER","source_url":"https://reporter.nih.gov/quickSearch/P50CA136393"},{"project":"P50CA136393","title":"Core D: Cancer Models","fiscal_year":2026,"amount_usd":"258666","organization":"MAYO CLINIC ROCHESTER","source_url":"https://reporter.nih.gov/quickSearch/P50CA136393"},{"project":"K12CA090628","title":"Paul Calabresi Program in Clinical/Translational Research at Mayo Clinic","fiscal_year":2025,"amount_usd":"771113","organization":"MAYO CLINIC ROCHESTER","source_url":"https://reporter.nih.gov/quickSearch/K12CA090628"}],"source":"grants"},"publications":{"total":50,"shown":5,"withheld":45,"matched_by":"OpenAlex author record","recent":[{"title":"Single-cell resolution of an open chromatin signature in persister tumor cells","year":2026,"journal":"Cell Reports","source_url":"https://doi.org/10.1016/j.celrep.2025.116708","status":"verified"},{"title":"Dual FAK and EPHA2 targeting by brigatinib tackles PARP inhibitor adaptive survival response in high-grade serous ovarian cancer","year":2026,"journal":"Science Translational Medicine","source_url":"https://doi.org/10.1126/scitranslmed.adt8706","status":"verified"},{"title":"Long-Term Survival in High-Grade Serous Ovarian Cancer Compared With the General US Population: A 30-Year Landmark Analysis","year":2026,"journal":"JCO oncology advances.","source_url":"https://doi.org/10.1200/oa-25-00142","status":"verified"},{"title":"Abstract CT075: Lack of CTPS2 expression exposes synthetic lethal vulnerability to selective CTPS1 inhibition: A phase 1 dose escalation study of dencatistat (STP938) with safety expansion in biomarker selected cohorts","year":2026,"journal":"Cancer Research","source_url":"https://doi.org/10.1158/1538-7445.am2026-ct075","status":"verified"},{"title":"Prehabilitation during neoadjuvant chemotherapy in advanced ovarian cancer is associated with improved surgical candidacy and chemotherapy outcomes","year":2026,"journal":"Gynecologic Oncology","source_url":"https://doi.org/10.1016/j.ygyno.2026.06.009","status":"verified"}],"source":"works"},"contact":{"address_1":"200 1ST ST SW","city":"Rochester","state":"MN","zip":"559050001","phone":"507-284-2511","source_url":"https://npiregistry.cms.hhs.gov/provider-view/1043415144","source":"identity"},"similar":[{"name":"Bradley Boeve","slug":"bradley-boeve","institution":"Mayo Clinic","specialty":"Neurology","url":"https://www.findmykol.com/kol/bradley-boeve","json_url":"https://www.findmykol.com/kol/bradley-boeve/profile.json"},{"name":"S Rajkumar","slug":"s-rajkumar","institution":"Mayo Clinic","specialty":"Hematology","url":"https://www.findmykol.com/kol/s-rajkumar","json_url":"https://www.findmykol.com/kol/s-rajkumar/profile.json"},{"name":"Victor Montori","slug":"victor-montori","institution":"Mayo Clinic","specialty":"Endocrinology, Diabetes & Metabolism","url":"https://www.findmykol.com/kol/victor-montori","json_url":"https://www.findmykol.com/kol/victor-montori/profile.json"},{"name":"Ayalew Tefferi","slug":"ayalew-tefferi","institution":"Mayo Clinic","specialty":"Hematology","url":"https://www.findmykol.com/kol/ayalew-tefferi","json_url":"https://www.findmykol.com/kol/ayalew-tefferi/profile.json"},{"name":"Carl June","slug":"carl-june","institution":"University of Pennsylvania","specialty":"Medical Oncology","url":"https://www.findmykol.com/kol/carl-june","json_url":"https://www.findmykol.com/kol/carl-june/profile.json"},{"name":"Rainer Storb","slug":"rainer-storb","institution":"University of Washington","specialty":"Hematology / Oncology","url":"https://www.findmykol.com/kol/rainer-storb","json_url":"https://www.findmykol.com/kol/rainer-storb/profile.json"},{"name":"Christina Fitzmaurice","slug":"christina-fitzmaurice","specialty":"Hematology / Oncology","url":"https://www.findmykol.com/kol/christina-fitzmaurice","json_url":"https://www.findmykol.com/kol/christina-fitzmaurice/profile.json"},{"name":"Beth Karlan","slug":"beth-karlan","institution":"University of California, Los Angeles","specialty":"Gynecologic Oncology","url":"https://www.findmykol.com/kol/beth-karlan","json_url":"https://www.findmykol.com/kol/beth-karlan/profile.json"}],"coverage":{"note":"A basic directory record. Sections absent here were not yet checked for this person, so absence means not yet looked, never none found.","not_yet_checked":["congress","network","presence","recognition"]},"not_included":{"note":"This document is the public layer: neutral facts cited to their source. Judgments (influence tier, archetype, trajectory commentary) and the itemized rows past each section's public teaser are account features and are not served here or to crawlers.","withheld_rows":{"payments":6,"funding":16,"publications":45}},"sources":{"orcid":{"name":"ORCID","url":"https://orcid.org","provides":"The verified researcher identity that anchors authorship"},"identity":{"name":"NPPES (CMS)","url":"https://npiregistry.cms.hhs.gov","provides":"Identity, specialty and practice location for every U.S. clinician","coverage":"Practice location (not mailing) from the NPPES record","record_last_updated":"2020-08-21","provider_certified":"2020-08-21","collected_at":"2026-11-03T00:00:00.000Z"},"works":{"name":"OpenAlex","url":"https://openalex.org","provides":"Citations, h-index, research topics, most-cited works and congress abstracts"},"payments":{"name":"CMS Open Payments","url":"https://openpaymentsdata.cms.gov","provides":"Industry payments reported to CMS, by company and program year","disclaimer":"Payments are publicly reported to CMS. Their existence does not imply wrongdoing; CMS does not interpret these data.","coverage":"Program years 2021 onward"},"medicare":{"name":"CMS Medicare Part D Prescribers and Part B","url":"https://data.cms.gov/provider-summary-by-type-of-service","provides":"Share of this prescriber's Medicare fee-for-service prescribing by drug class and therapeutic area, classified with WHO ATC and NLM RxClass","disclaimer":"Proportions of the prescriber's own classified prescribing, never patient counts or dollar amounts. Fee-for-service only; CMS publishes about 17 months after the fact and suppresses counts of ten patients or fewer.","data_year":2024},"grants":{"name":"NIH RePORTER","url":"https://reporter.nih.gov","provides":"Federally funded research awards, by fiscal year"}},"methodology_url":"https://www.findmykol.com/about#methodology"}